WO2010042743A3 - Multiplexes chimères, compositions et procédés permettant de les utiliser - Google Patents

Multiplexes chimères, compositions et procédés permettant de les utiliser Download PDF

Info

Publication number
WO2010042743A3
WO2010042743A3 PCT/US2009/060040 US2009060040W WO2010042743A3 WO 2010042743 A3 WO2010042743 A3 WO 2010042743A3 US 2009060040 W US2009060040 W US 2009060040W WO 2010042743 A3 WO2010042743 A3 WO 2010042743A3
Authority
WO
WIPO (PCT)
Prior art keywords
multiplexes
chimeric
compositions
methods
same
Prior art date
Application number
PCT/US2009/060040
Other languages
English (en)
Other versions
WO2010042743A2 (fr
Inventor
Miguel De Los Rios
Timothy L. Bullock
Kenneth J. Oh
Patrick T. Johnson
Jacek Ostrowski
Original Assignee
Chimeros Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimeros Inc. filed Critical Chimeros Inc.
Publication of WO2010042743A2 publication Critical patent/WO2010042743A2/fr
Publication of WO2010042743A3 publication Critical patent/WO2010042743A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141—Use of virus, viral particle or viral elements as a vector
    • C12N2730/10142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des multiplexes chimères thérapeutiques comprenant au moins deux capsides constituées, par exemple, d'une protéine centrale virale modifiée et d'un acide nucléique lié à la protéine centrale virale modifiée. L'acide nucléique peut être sensiblement homologue à une cible du gène spécifique. Dans certains modes de réalisation, l'acide nucléique lié à la protéine centrale virale modifiée est essentiellement non-immunogène.
PCT/US2009/060040 2008-10-08 2009-10-08 Multiplexes chimères, compositions et procédés permettant de les utiliser WO2010042743A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10384308P 2008-10-08 2008-10-08
US61/103,843 2008-10-08

Publications (2)

Publication Number Publication Date
WO2010042743A2 WO2010042743A2 (fr) 2010-04-15
WO2010042743A3 true WO2010042743A3 (fr) 2010-10-28

Family

ID=42101213

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/060040 WO2010042743A2 (fr) 2008-10-08 2009-10-08 Multiplexes chimères, compositions et procédés permettant de les utiliser

Country Status (1)

Country Link
WO (1) WO2010042743A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014527072A (ja) * 2011-09-09 2014-10-09 バイオメド リアルティー， エル．ピー． ウイルスタンパク質の集合を制御するための方法および組成物
GB201214746D0 (en) * 2012-08-17 2012-10-03 Cancer Rec Tech Ltd Biomolecular complexes
WO2020139843A1 (fr) 2018-12-28 2020-07-02 The Board Of Trustee Of The Leland Stanford Junior University Polypeptide noyau de l'hépatite b génétiquement modifié
JP2023534054A (ja) * 2020-07-17 2023-08-07 養生堂有限公司 細胞透過性ペプチドおよびその使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020064533A1 (en) * 1998-12-04 2002-05-30 Kenneth Murray HBV core antigen particles with multiple immunogenic components attached via peptide ligands
US20030175290A1 (en) * 2001-01-19 2003-09-18 Cytos Biotechnology Ag Molecular antigen array
US20040059094A1 (en) * 2002-07-18 2004-03-25 Bachmann Martin F. Hapten-carrier conjugates and uses thereof
US20060216702A1 (en) * 2002-05-17 2006-09-28 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020064533A1 (en) * 1998-12-04 2002-05-30 Kenneth Murray HBV core antigen particles with multiple immunogenic components attached via peptide ligands
US20030175290A1 (en) * 2001-01-19 2003-09-18 Cytos Biotechnology Ag Molecular antigen array
US20060216702A1 (en) * 2002-05-17 2006-09-28 Compans Richard W Virus-like particles, methods of preparation, and immunogenic compositions
US20040059094A1 (en) * 2002-07-18 2004-03-25 Bachmann Martin F. Hapten-carrier conjugates and uses thereof

Also Published As

Publication number Publication date
WO2010042743A2 (fr) 2010-04-15

Similar Documents

Publication Publication Date Title
WO2010042749A3 (fr) Agents thérapeutiques chimères, compositions et procédés permettant de les utiliser
WO2010042751A3 (fr) Agents thérapeutiques chimères, compositions et procédés permettant de les utiliser
WO2010042755A3 (fr) Agents thérapeutiques chimères, compositions et méthodes d'utilisation
WO2012045082A3 (fr) Synthèse d'acides nucléiques et méthodes d'utilisation associées
WO2012075040A3 (fr) Arnm pour l'utilisation dans le traitement de maladies génétiques humaines
WO2012135805A3 (fr) Administration et formulation d'acides nucléiques génétiquement modifiés
WO2012019168A3 (fr) Acides nucléiques modifiés et leurs procédés d'utilisation
WO2007130604A3 (fr) ACTIVITÉ ANTI-TUMORALE D'UN ARNsi ONCOGÉNIQUE ADMINISTRÉ PAR UN ADÉNOVIRUS ONCOLYTIQUE
WO2007095316A3 (fr) Compositions et procédés pour formulations à base d'oligonucléotides
EP2274442A4 (fr) Séquences consensus de protéines du virus chikungunya, molécules d acide nucléique codant pour celles-ci, et compositions et procédés d utilisation de celles-ci
WO2008104890A3 (fr) Compositions et procédés de production d'apolipoprotéine
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
WO2009149956A3 (fr) Protéine de fusion et son utilisation
WO2008028117A3 (fr) Miméticorps glp-2, polypeptides, compositions, procédés et utilisations
WO2007092704A3 (fr) Gènes destinés à augmenter l'efficacité d'utilisation de l'azote dans des plantes cultivées
WO2015035162A3 (fr) Variants de cas9 et leurs utilisations
WO2009099641A3 (fr) Compositions protéiniques stabilisées
WO2010127304A3 (fr) Procédés de séquençage
WO2009042186A3 (fr) Edition génomique dans un dard-perche à l'aide de nucléases à doigt de zinc
WO2011072246A3 (fr) Modification de l'adn induite par l'effecteur tal
WO2014106015A3 (fr) Compositions protéiques à liaison multivalente
WO2008067423A3 (fr) Procédé d'amélioration de l'introduction d'adn dans des cellules bactériennes
WO2012024526A3 (fr) Conjugués, particules, compositions et procédés associés
EP2224912A4 (fr) Compositions et procédés améliorés pour la délivrance d'acides nucléiques
WO2008011446A3 (fr) Mimétiques de la glp-1 humaine, compositions, procédés et utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09819899

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16/06/2011)

122 Ep: pct application non-entry in european phase

Ref document number: 09819899

Country of ref document: EP

Kind code of ref document: A2